Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection
about
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsTenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelPharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.Selective pinning control of the average disease transmissibility in an HIV contact network.Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.
P2860
Q27324453-3D440891-BE64-410D-9E96-5B0129876F3CQ28547109-13E84C93-1369-4350-968C-73F7713C6090Q34034418-06F49593-66AA-441A-81AF-15EFC65607C7Q34202159-ABD8A36E-EBB4-4D7E-B937-FE730AD28E8FQ34571360-6DDF7BA9-621D-434D-9AEB-5F1313E33AD6Q34658079-13DCC04C-8FB5-48DB-8490-2AB0444509EEQ35473669-9100B99C-0BF9-4759-B76E-0372C44A4E04Q35668556-199634C1-9AAE-4211-8686-29C38B4BBE4EQ36188725-F273EC28-BBF2-49D3-939E-A0C5ED4142F2Q36933427-F6F20870-FFCC-4B19-98D0-14008E31C110Q37114554-209E2788-2C98-41E0-A597-B3A68A39BC12Q37126494-5AF1A83A-2765-4FBC-AC46-209331BDA51BQ37203867-CBF1022F-4859-4CBF-AB2C-B5E3855D5442Q37210864-1AC87060-B179-488A-A018-DD6B29396C5FQ37224902-98DBB3C9-13FC-42C5-A4F3-68B354F7943EQ39127005-411F5203-69AA-452D-ADCC-1C95B455DF58Q39488594-44691936-B0F9-4C69-A9AC-3DD0CA9C1590Q41052040-30FD21E4-055C-41B2-8E03-42299ECBB9EDQ51166879-2E285365-BE72-44A3-B437-205F99B2EB39Q55299659-D0284E9C-B5DD-4E22-984C-5968859BE912
P2860
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@ast
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@en
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@nl
type
label
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@ast
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@en
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@nl
prefLabel
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@ast
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@en
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@nl
P2860
P3181
P1433
P1476
Pharmacokinetics and pharmacod ...... ficacy against HIV-1 infection
@en
P2093
Christof Schütte
Sulav Duwal
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0040382
P407
P577
2012-01-01T00:00:00Z